As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Foghorn Therapeutics Inc. The largest reported stake is Flagship Ventures Fund V, L.P.'s, at 27.2%. 5 filings are on record since January 13, 2026 (Schedule 13D/A, January 13, 2026).
Who owns Foghorn Therapeutics Inc.?
Sell to companies like Foghorn Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Biotechnology Value Fund L P · Sole voting: 0 · Shared voting: 4,494,462 · Sole dispositive: 0 · Shared dispositive: 4,494,462 · SCHEDULE 13G/A, 2026-10-05
- · Holder: Bvf Partners L P · Percent: 9.99% · SCHEDULE 13G/A
- · Reporting person: Deerfield Mgmt, L.P. · Sole voting: 5,139,523 · Shared voting: 0 · Sole dispositive: 5,139,523 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-14
- · Reporting person: Fmr LLC · Sole voting: 6,789,916 · Shared voting: 0 · Sole dispositive: 6,792,356 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-06
- · Holder: Flagship Ventures Fund V, L.P. · Percent: 27.2% · SCHEDULE 13D/A
Foghorn Therapeutics Inc. has 5 Schedule 13D or 13G filings on record since 2026-01-13. 4 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: about 65 jobs, latest 2026-10-01 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Flagship Ventures Fund V, L.P. | 27.2% | 9,330,878 | SCHEDULE 13D/A, 2026-01-13 | 2026-01-09 |
| Bvf Partners L P | 14.3% | 8,507,000 | SCHEDULE 13G/A, 2026-10-05 | 2026-10-01 |
| Fmr LLC | 11.6% | 6,792,356 | SCHEDULE 13G/A, 2026-05-06 | 2026-03-31 |
| Deerfield Mgmt, L.P. | 8.64% | 5,139,523 | SCHEDULE 13G/A, 2026-05-14 | 2026-03-31 |
Holding shares or following this stake? See who's behind Foghorn Therapeutics Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Foghorn Therapeutics Inc. and the records around it.
Foghorn Therapeutics Inc. elsewhere on the record
Companies that share a holder
- Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Stoke Therapeutics, Inc. (Sep 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Foghorn Therapeutics Inc.
Get an email when Foghorn Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Foghorn Therapeutics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Foghorn Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Foghorn Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Biotechnology Value Fund L P | 0 | 4,494,462 | 0 | 4,494,462 | SCHEDULE 13G/A, 2026-10-05 |
| Bvf I Gp LLC | 0 | 4,494,462 | 0 | 4,494,462 | SCHEDULE 13G/A, 2026-10-05 |
| Biotechnology Value Fund Ii LP | 0 | 3,232,448 | 0 | 3,232,448 | SCHEDULE 13G/A, 2026-10-05 |
| Bvf Ii Gp LLC | 0 | 3,232,448 | 0 | 3,232,448 | SCHEDULE 13G/A, 2026-10-05 |
| Biotechnology Value Trading Fund OS LP | 0 | 619,258 | 0 | 619,258 | SCHEDULE 13G/A, 2026-10-05 |
| BVF Partners OS Ltd. | 0 | 619,258 | 0 | 619,258 | SCHEDULE 13G/A, 2026-10-05 |
| Bvf Gp Holdings LLC | 0 | 7,726,910 | 0 | 7,726,910 | SCHEDULE 13G/A, 2026-10-05 |
| Bvf Partners L P | 0 | 8,507,000 | 0 | 8,507,000 | SCHEDULE 13G/A, 2026-10-05 |
| Bvf Inc | 0 | 8,507,000 | 0 | 8,507,000 | SCHEDULE 13G/A, 2026-10-05 |
| Lampert Mark N | 0 | 8,507,000 | 0 | 8,507,000 | SCHEDULE 13G/A, 2026-10-05 |
| Fmr LLC | 6,789,916 | 0 | 6,792,356 | 0 | SCHEDULE 13G/A, 2026-05-06 |
| Abigail P. Johnson | 0 | 0 | 6,792,356 | 0 | SCHEDULE 13G/A, 2026-05-06 |
| Deerfield Mgmt, L.P. | 5,139,523 | 0 | 5,139,523 | 0 | SCHEDULE 13G/A, 2026-05-14 |
| Deerfield Management Company, L.P. | 5,139,523 | 0 | 5,139,523 | 0 | SCHEDULE 13G/A, 2026-05-14 |
| Deerfield Partners, L.P. | 5,139,523 | 0 | 5,139,523 | 0 | SCHEDULE 13G/A, 2026-05-14 |
| James E. Flynn | 5,139,523 | 0 | 5,139,523 | 0 | SCHEDULE 13G/A, 2026-05-14 |
The latest filing identifies Foghorn Therapeutics Inc. by CUSIP 344174107 and gives its principal executive office as 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE, MA 02139 (SCHEDULE 13G/A, 2026-10-05).
What the percentages are based on
The following percentages are based upon 59,385,315 Shares outstanding as of July 31, 2026, which is the total number of Shares outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2026.Bvf Partners L P, SCHEDULE 13G/A, 2026-10-05
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-01-13 | Flagship Ventures Fund V, L.P. | 27.2% | SCHEDULE 13D/A |
| 2026-05-06 | Fmr LLC | 11.6% | SCHEDULE 13G/A |
| 2026-05-14 | Deerfield Mgmt, L.P. | 8.64% | SCHEDULE 13G/A |
| 2026-05-15 | Bvf Partners L P | 9.99% | SCHEDULE 13G/A |
| 2026-10-05 | Bvf Partners L P | 14.3% | SCHEDULE 13G/A |
Questions about who owns Foghorn Therapeutics Inc.
Who owns Foghorn Therapeutics Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Foghorn Therapeutics Inc.: Flagship Ventures Fund V, L.P. (27.2%, Schedule 13D/A, filed 2026-01-13), Bvf Partners L P (14.3%, Schedule 13G/A, filed 2026-10-05), Fmr LLC (11.6%, Schedule 13G/A, filed 2026-05-06) and Deerfield Mgmt, L.P. (8.64%, Schedule 13G/A, filed 2026-05-14).
Who are the largest shareholders of Foghorn Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of Foghorn Therapeutics Inc. on this page are Flagship Ventures Fund V, L.P. (27.2%), Bvf Partners L P (14.3%) and Fmr LLC (11.6%).
When did Flagship Ventures Fund V, L.P. buy into Foghorn Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Flagship Ventures Fund V, L.P. on this page is the Schedule 13D/A, filed 2026-01-13, reporting 27.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Foghorn Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.